Eton Pharmaceuticals (ETON)
NASDAQ:ETON
Want to see ETON full AI Analyst Report?
ETON Stock Chart & Stats
$25.04
-$0.03(-0.25%)
At close: 4:00 PM EST
$25.04
-$0.03(-0.25%)
Day’s Range― - ―
52-Week Range$13.09 - $35.66
Previous CloseN/A
Volume127.06K
Average Volume (3M)411.95K
Market Cap
$834.10M
Enterprise Value$826.68M
Total Cash (Recent Filing)$19.66M
Total Debt (Recent Filing)$12.25M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 06, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding27,392,359
10 Day Avg. Volume471,969
30 Day Avg. Volume411,953
Financial Highlights & Ratios
PEG Ratio-7.42
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue9.51
Enterprise Value/Gross Profit17.36
Enterprise Value/Ebitda145.08
Forecast
1Y Price Target
$48.50Price Target Upside93.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.8
Revenue Forecast (FY)$113.39M
Bulls Say, Bears Say
Bulls Say
Commercial Launch ExecutionA commercial launch that leverages a specialty pharmacy for distribution and an established pediatric rare disease sales force can facilitate targeted access to specialty providers and accelerate uptake in orphan markets.
Formulation And Dosing AdvantageAn oral liquid formulation enables more precise and flexible dosing than tablets and can attract patients and caregivers who prefer liquid medication, reducing dosing challenges for those needing adjusted doses.
Regulatory Label ExpansionA broad FDA label without age restrictions expands the drug's addressable market to include adult patients as well as pediatric patients, increasing potential patient population and revenue opportunities.
Bears Say
Adult Market Penetration RiskPenetration into the adult population may be lower than in pediatrics, which could limit expected market expansion and revenue upside from broader labeling.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $13.09 and its highest was $35.66 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $834.10M.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 66 days.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.027.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.15.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 27,392,359 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of $0.14 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 1.001%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.50 (93.69% Upside)
$48.50 (93.69% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 75.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.94%
12-Months-Change
Fundamentals
Return on Equity
-5.68%
Trailing 12-Months
Asset Growth
16.28%
Trailing 12-Months
Company Description
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: record product revenue (73% YoY), successful launches of DESMODA and HEMANGEOL, raised full‑year guidance (> $120M), improving adjusted EBITDA and multiple high‑value pipeline milestones (INCRELEX label study cleared, ET‑700 and Amglidia progress). Operational scalability was highlighted by relatively modest G&A growth versus revenue growth. Key risks discussed include launch execution and reimbursement uncertainty for HEMANGEOL (large portion of volume potentially near‑zero revenue), modest margin dilution from ex‑U.S. INCRELEX shipments, higher recurring FDA program fees, and near‑term cash impacts from the HEMANGEOL acquisition. On balance, the positive commercial performance, upgraded guidance, and clear pipeline catalysts outweigh the near‑term uncertainties reported.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$48.50
▲(93.69% Upside)
Technical Analysis
Ownership Overview
15.43% Insiders
6.86% Mutual Funds
37.13% Other Institutional Investors
32.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---